The FDA will now allow biotechs to ask agency staff for “quick clarifications” via email. Elsewhere, Novartis hiked guidance for two top drugs and a startup nearing “unicorn” status secured a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback